Lv2
182 积分 2023-08-01 加入
P4.07D.04 Trofuse-019: A Phase 3 Study of Adjuvant Pembrolizumab with or without Sac-TMTfor Resectable Stage II-IIIB (N2) NSCLC
1天前
求助中
Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC
21天前
已关闭
The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development
22天前
已完结
Prognostic factors in patients with advanced non-small cell lung cancer: Data from the phase III FLEX study
23天前
已完结
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
23天前
已完结
Metabolic communication in the tumour–immune microenvironment
27天前
已完结
An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma
28天前
已完结
Cancer therapy with antibodies
29天前
已完结
Engineering IL-2 for immunotherapy of autoimmunity and cancer
1个月前
已完结
Exploiting a natural conformational switch to engineer an interleukin-2 ‘superkine’
1个月前
已完结
皖公网安备34019202002308
